Schering-Plough has extended the phase II study with vicriviroc, its investigational CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type virus only. The
AdviTech has completed its initial funding round by securing commitments of $3.4 million, including $2.5 million from the Texas Emerging Technology Fund (ETF). Wesley Krueger, chairman and chief
Abbott has announced strong financial results for the second quarter ended June 30, 2009. Diluted earnings per share, excluding specified items, were $0.89, at the high end of
Celesio has acquired Laboratoria Flandria. The acquisition is an addition to the existing network of Celesio’s Belgian subsidiaries. The company expects to utilise further synergies and to offer
Cornerstone has submitted a regulatory filing with the Food and Development Authority (FDA) for an extended-release antitussive product – CRTX 067. Craig Collard, president and CEO of Cornerstone,
IBM has signed a five-year information technology services agreement with the Dow Chemical Company. As part of the agreement, IBM will help with the integration of Rohm and
Baxter and Halozyme have completed patient enrollment in the phase III pivotal study of Gammagard Liquid with rHuPH20 (recombinant human hyaluronidase enzyme). It is to be used for
Based on the data presented, the FDA’ Oncologic Drugs Advisory Committee (ODAC) recommended that the combination of Doxil (doxorubicin HCI liposome injection) and docetaxel did not provide a
FDA’ Oncologic Drugs Advisory Committee (ODAC) said that the combination of trabectedin, when administered with Doxil (doxorubicin HCI liposome injection), did not provide a sufficient benefit-risk profile for
Nature & Health is conducting a voluntary nationwide recall of the five supplement products sold under the following names: LibieXtreme, Y-4ever, Libimax X Liquid, Powermania Liquid and Capsule,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.